At ExhaleRx, we work with multiple self-funded plans and PBM-aligned groups facing a similar challenge:

👉 A small group of medications accounting for a disproportionate share of total spend

This is one recent example that reflects what we consistently see across plans.

The primary cost drivers included:

💉 Lupron Depot
💉 Stelara
💉 Ozempic
💉 Trulicity
💉 Xolair
💊 Jardiance
💊 Farxiga
💊 Xarelto
💊 Glyxambi
💊 Entresto
💊 Otezla
📟 Dexcom G7 Sensors
💉 Semglee
💊 Xigduo XR
💊 Dificid
💊 Paxlovid

Alongside continued utilization of high-cost biologics:

Humira | Enbrel | Skyrizi | Tremfya | Cosentyx | Rinvoq | Dupixent

⚠️ The Common Problem

Across plans, we typically see:

📈 Per-script costs exceeding $20,000
📈 Increasing demand across GLP-1 and specialty medications
📈 Pricing inconsistencies between suppliers
📈 Limited transparency into true acquisition cost

⚙️ The ExhaleRx Model

What differentiates ExhaleRx is not just access — it’s execution at scale, particularly on logistics.

UK-Based

Reliable access to branded medications

❄️ Best-in-Class Cold Chain Logistics

This is where we consistently outperform:

• Advanced temperature-controlled packaging
• Strict handling protocols from dispatch to delivery
• Average 36-hour average delivery as soon as order is received
• Designed to eliminate delays and protect product integrity

📦 Speed + Reliability for High-Value Therapies

Our model is built specifically for specialty and GLP-1 medications, where timing and handling are critical

📊 Formulary-Level Cost Alignment

Reducing spread and normalizing pricing across high-cost categories

🔗 Direct Supply Chain Access

Fewer intermediaries, tighter control, better economics

✅ The Result (Typical Outcome)

💰 Meaningful reduction in per-script costs
💰 Stabilized pricing across key therapies
💰 Significant savings on specialty biologics
💰 Six-figure annualized savings potential per plan

All while maintaining:

✔️ Branded medications only
✔️ No disruption to patient care
✔️ Full operational transparency

💡 The Reality Across Plans

This isn’t a one-off result — it’s a repeatable model.

Most plans try to reduce costs by limiting access.
We focus on optimizing how medications are sourced, handled, and delivered — where the biggest inefficiencies exist.

That’s where ExhaleRx consistently delivers results. 🚀

📩 If your plan is seeing similar cost concentration across specialty or GLP-1 medications, happy to share how this model can be applied.

#ExhaleRx
#SpecialtyPharmacy
#GLP1
#Enbrel
#Skyrizi
#Rinvoq
#Humira
#Dupixent
#Stelara
#Cimzia
#Ozempic
#Wegovy
#Mounjaro
#SelfFundedPlans
#SelfInsuredEmployers
#PBMs
#DPC
#SpecialtyMedications
#ChronicCare
#ChronicConditions
#DiabetesManagement
#Type2Diabetes
#WeightLoss
#PharmaSavings
#HealthcareSavings
#CostSavings
#BenefitOptimization
#EmployeeHealth
#WellnessSolutions
#AffordableHealthcare
#BrandedMedications
#MedicationAccess
#ColdChain
#PharmacyLogistics
#PharmacyInnovation
#HealthcareInnovation
#IntegratedCare
#PatientCare
#SustainableHealthcare